L-DOPA-induced dyskinesia (LID) is one of the main limitations of long term L-DOPA use in Parkinson's disease (PD) patients. We show that chronic L-DOPA treatment induces novel dyskinetic behaviors in aphakia mouse with selective nigrostriatal deficit mimicking PD. The stereotypical abnormal involuntary movements were induced by dopamine receptor agonists and attenuated by antidyskinetic agents. The development of LID was accompanied by preprodynorphin and preproenkephalin expression changes in the denervated dorsal striatum. Increased FosB-expression was also noted in the dorsal striatum. In addition, FosB expression was noted in the pedunculopontine nucleus and the zona incerta, structures previously not examined in the setting of LID. The aphakia mouse is a novel genetic model with behavioral and biochemical characteristics consistent with those of PD dyskinesia and provides a more consistent, convenient, and physiologic model than toxic lesion models to study the mechanism of LID and to test therapeutic approaches for LID.
Introduction
L-DOPA-induced dyskinesia (LID) is one of the most significant limitations of chronic L-DOPA treatment in Parkinson's disease (PD) patients, and extensive investigations have been undertaken to understand the mechanism of LID (Linazasoro, 2005) using both primate (Marin et al., 2006; Boyce et al., 1990a ) and rodent models of PD (Cenci et al., 1998; Andersson et al., 1999; Lundblad et al., 2004; Winkler et al., 2002; Johnston et al., 2005; Kovoor et al., 2005; Pavon et al., 1996; Picconi et al., 2003) . Primate models show behaviors that are closest to human LID (Marin et al., 2006) , but the logistics of using primates limit the ability to use primates widely. Recent hemi-Parkinsonian rodent models created by unilateral toxic lesions of the nigrostriatal projection (Cenci et al., 1998; Andersson et al., 1999; Lundblad et al., 2002 Lundblad et al., , 2004 allow a more accessible model to study LID, but they have the limitation in generating consistent and selective lesions without high mortality (Barneoud et al., 2000; Chang et al., 1999; Truong et al., 2006) . Pharmacological depletion of monoamines by reserpine has been proposed as a model to study LID, and has the advantage of a fast screening tool. However, this is an acute model whereas LID typically develops over time and the depletion of monoamine is more extensive than seen in PD (Johnston et al., 2005; Kovoor et al., 2005 ). An ideal model of LID should have: (1) selective loss of nigrostriatal lesions mimicking PD; (2) consistent and stable degree of lesion with minimal recovery, variability, and mortality; (3) high percentage of animals developing dyskinesia; (4) differentiation of acute and chronic L-DOPA effects on the behaviors.
The aphakia mice selectively lose dopamine neurons in the midbrain, especially in the substantia nigra (SN) as a consequence of a naturally occurring deletion of the promoter region and the noncoding exon 1 of the Pitx3 gene (Hwang et al., 2003; Nunes et al., 2003; van den Munckhof et al., 2003; Smidt et al., 2004) . Consistent with the loss of DA neurons in the SN, there is significant DA denervation in the dorsal striatum (Hwang et al., 2003) , which results in the motor deficits that are rescued by L-DOPA (Hwang et al., 2003; van den Munckhof et al., 2006) . In addition, adaptation to the denervation and evidence for the supersensitivity of striatal dopamine receptors (DR) were noted (Hwang et al., 2005;  
